Project Grant HT94252410591
Award Date 9/1/24
Completion Date 8/31/28
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- This Project Grant award of $577,680.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research by the University of Colorado to target EHMT1/2 in order to overcome therapy-resistant ovarian cancer. The project will run from May 1, 2025 to April 30, 2029. As a prominent public research university, the University of Colorado has a robust portfolio of federal contract and grant awards across multiple scientific and technological...
- The federal Project Grant award for "TARGETING EHMT1/2 TO OVERCOME THERAPY-RESISTANT OVARIAN CANCER" was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,260,839 award, which commenced on May 1, 2025 and is scheduled for completion by April 30, 2029, supports advanced biomedical research to develop innovative medical solutions that address critical health challenges for military personnel and the broader public. The...
- The federal Project Grant award of $2,271,024.00 was provided by the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) federal grant program, to the University of Colorado-Denver. The award, effective November 1, 2024, supports a four-year research project to improve understanding of next-generation immunotherapy responses in metastatic uveal melanoma. The University of Colorado-Denver, a major public research university with a strong focus on medical...
- This federal Project Grant award in the amount of $624,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Colorado-Denver. The grant will fund a 2-year project from July 1, 2024 to June 30, 2026 to investigate the use of cell-free DNA to define MYC activity in osteosarcoma. The University of Colorado-Denver, a major public research institution, will serve as the primary awardee and perform the research...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $780,000.00 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to support research on "An Unconventional Pathway to Melanoma Development and Prevention". The research aims to investigate innovative approaches to address melanoma, a serious form of skin cancer, with the goal of improving...
- This $2,131,064 federal Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to the University of Colorado-Denver supports research on the effects of androgen receptors in luminal breast cancer. The four-year project, titled "ANDROGEN RECEPTORS IN LUMINAL BREAST CANCER: EFFECTS ON RESPONSE TO ENDOCRINE THERAPY AND AN IMMUNE-SUPPRESSIVE TUMOR IMMUNE MICROENVIRONMENT (TIME)", aims to investigate how androgen receptor...
- This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,225,783.00 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to develop a fully automated deep learning-based framework for segmentation and treatment response assessment of lesions on PSMA PET/CT in prostate cancer. The award period runs from Sep 1, 2025 to Aug 31, 2028. The University of Colorado-Denver, a...
- The Defense Health Agency awarded a $320,000 Project Grant to the Regents of the University of Colorado Denver under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2025 to determine the mechanisms underlying remyelination by surviving oligodendrocytes. The research aims to advance understanding of how the central nervous system repairs myelin sheaths, with potential implications for treating multiple...
- The federal Project Grant award in the amount of $999,793.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). This award is supporting research by the Regents of the University of Colorado, specifically the University of Colorado Office of Contracts and Grants Division, to conduct targeted suppression of rodent models for multiple sclerosis (MS). The grant aims to deliver fundamental research and develop specialized data...
- This $2,488,002.00 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports a multi-year research effort by the University of Colorado-Denver to develop biomarkers for detecting acute, subacute, and chronic organ injury following neonatal congenital heart disease surgery. The research aims to improve diagnostic capabilities and treatment outcomes for this patient population. The award runs from April 1, 2024 to March 31, 2028, and...